A Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Uterine Fibroids

Trial Profile

A Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Uterine Fibroids

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Fezolinetant (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Sponsors Ogeda
  • Most Recent Events

    • 10 Mar 2017 This trial was completed in Austria(End date: 05 Dec 2016).
    • 26 Feb 2017 This trial was completed in Belgium and Germany (End date: 05 Dec 2016).
    • 19 Jul 2016 According to an Euroscreen media release, the company has opened an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to conduct pivotal efficacy and safety assessments to evaluate ESN364 in Phase II studies for the treatment of menopausal hot flashes, poly cystic ovary syndrome and uterine fibroids.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top